MONDAY, July 21 (HealthDay News) -- The controversial cholesterol drug Vytorin does not lower the risk of major heart valve problems, according to a report released Monday by its manufacturers, Schering-Plough Corp. and Merck & Co.
In a multi-country study of 1,873 patients, the drug was no better than placebo at lowering the odds of major cardiovascular events in patients suffering from aortic stenosis, a condition involving blocked blood flow to the heart.
